干细胞用于1型糖尿病(T1D)的细胞和分子治疗:梦想与现实的差距。

IF 1.5 Q4 CELL BIOLOGY
American journal of stem cells Pub Date : 2015-03-15 eCollection Date: 2015-01-01
Riccardo Calafiore, Giuseppe Basta
{"title":"干细胞用于1型糖尿病(T1D)的细胞和分子治疗:梦想与现实的差距。","authors":"Riccardo Calafiore,&nbsp;Giuseppe Basta","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In spite of intense research, over the past 2-3 decades, targeted to validating methods for the cure of T1D, based on cell substitution therapy in the place of exogenously administered insulin injections, achievement of the final goal continues to remain out of reach. In fact, aside of very limited clinical success of the few clinical trials of pancreatic islet cell transplantation in totally immunosuppressed patients with T1D, the vast majority of these diabetic patients invariably is insulin-dependent. New advances for cell and molecular therapy for T1D, including use of stem cells, are reviewed and discussed in an attempt to clearly establish where we are and where are we may go for the final cure for T1DM. </p>","PeriodicalId":7657,"journal":{"name":"American journal of stem cells","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2015-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396156/pdf/ajsc0004-0022.pdf","citationCount":"0","resultStr":"{\"title\":\"Stem cells for the cell and molecular therapy of type 1 diabetes mellitus (T1D): the gap between dream and reality.\",\"authors\":\"Riccardo Calafiore,&nbsp;Giuseppe Basta\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In spite of intense research, over the past 2-3 decades, targeted to validating methods for the cure of T1D, based on cell substitution therapy in the place of exogenously administered insulin injections, achievement of the final goal continues to remain out of reach. In fact, aside of very limited clinical success of the few clinical trials of pancreatic islet cell transplantation in totally immunosuppressed patients with T1D, the vast majority of these diabetic patients invariably is insulin-dependent. New advances for cell and molecular therapy for T1D, including use of stem cells, are reviewed and discussed in an attempt to clearly establish where we are and where are we may go for the final cure for T1DM. </p>\",\"PeriodicalId\":7657,\"journal\":{\"name\":\"American journal of stem cells\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2015-03-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396156/pdf/ajsc0004-0022.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of stem cells\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2015/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of stem cells","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

尽管在过去的二、三十年中进行了大量的研究,旨在验证以细胞替代疗法代替外源性胰岛素注射治疗T1D的方法,但最终目标的实现仍然遥不可及。事实上,除了对完全免疫抑制的T1D患者进行胰岛细胞移植的少数临床试验非常有限的临床成功外,绝大多数这些糖尿病患者都是胰岛素依赖的。本文回顾和讨论了T1DM细胞和分子治疗的新进展,包括干细胞的使用,试图清楚地确定我们在T1DM的最终治疗中所处的位置以及我们可能走向的方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Stem cells for the cell and molecular therapy of type 1 diabetes mellitus (T1D): the gap between dream and reality.

In spite of intense research, over the past 2-3 decades, targeted to validating methods for the cure of T1D, based on cell substitution therapy in the place of exogenously administered insulin injections, achievement of the final goal continues to remain out of reach. In fact, aside of very limited clinical success of the few clinical trials of pancreatic islet cell transplantation in totally immunosuppressed patients with T1D, the vast majority of these diabetic patients invariably is insulin-dependent. New advances for cell and molecular therapy for T1D, including use of stem cells, are reviewed and discussed in an attempt to clearly establish where we are and where are we may go for the final cure for T1DM.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信